Aelis Farma

AELIS

FR0014007ZB4

Aelis Farma is specialized in the research and development of drugs for the treatment of major disorders of the Central Nervous System (CNS). The company has 2 products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome, Fragile X syndrome, Subjective Memory Impairment (SMI) and Alzheimer's disease).

Sector

Pharmaceuticals

Calendar

2024-06-03 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Aelis Farma

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13 EUR

Average target price

20.67 EUR

Spread / Average Target

+58.97%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AELIS FARMA	0.00%	182M
ELI LILLY AND COMPANY	+25.52%	661B
NOVO NORDISK A/S	+26.74%	566B
JOHNSON & JOHNSON	-6.59%	352B
MERCK & CO., INC.	+20.23%	332B
ABBVIE INC.	+2.95%	283B
ASTRAZENECA PLC	+13.43%	231B
NOVARTIS AG	+4.71%	200B
ROCHE HOLDING AG	-9.53%	195B
AMGEN INC.	-5.20%	145B

Other Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 07:03:12 2024-04-29 am EDT			5-day change	1st Jan Change
13.1 ^EUR	+0.77%		0.00%	0.00%

Apr. 18	Aelis Farma SA Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder	CI
Apr. 02	Aelis Farma SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Aelis Farma SA Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder	Apr. 18	CI
Aelis Farma SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
Aelis Farma Appoints Chief Corporate Development Officer	Jan. 18	MT
Aelis Farma Announces the Appointment of Arsène Guekam as Chief Corporate Development Officer	Jan. 17	CI
Aelis Farma Announces Completion of Patient Randomization for Phase 2B Study with Aef0117 for the Treatment of Cannabis Addiction	Jan. 09	CI
Aelis Farma Announces Positive Results of Non-Clinical Studies Required by Regulatory Agencies to Enter Its First Cb1-SSI, AEF0117, in Phase 3 Clinical Trial for the Treatment of Cannabis Use Disorder	Nov. 07	CI
Aelis Farma SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-25	CI
Aelis Farma: CEO and co-founder recognized by his peers	23-08-29	CF
Data Safety Monitoring Board OKs Aelis Farma's Mid-stage Trial of Cannabis Addiction Drug	23-07-05	MT
Aelis Farma: received a positive opinion from the DSMB	23-07-05	CF
Aelis Farma Receives a Positive Recommendation From the DSMB to Continue, With No Modification to the Protocol, the Phase 2b Clinical Study With AEF0117 in Cannabis Addiction	23-07-05	CI
Aelis Farma: favorable preclinical data in autism	23-06-12	CF
Aelis Farma Announces the Presentation of New Preclinical Data on its Drug Candidate AEF0217 at the 2nd European Conference on Phelan-McDermid Syndrome	23-06-12	CI
CAC40: ends in green, ignores eurozone recession	23-06-08	CF
Aelis Farma: promising results for AEF0117	23-06-08	CF
Aelis Farma SA Approves Transfer of Registered Office	23-05-25	CI
AELIS FARMA : Degroof Petercam initiates buy coverage	23-04-24	CF
Aelis Farma SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-03	CI
Aelis Farma Begins Patient Recruitment for Trial of Cognitive Disorder Treatment	22-12-16	MT
Aelis Farma S.A Announces the Recruitment of the First Patient for the Phase 1/2 Clinical Trial of Its Drug Candidate AEF0217 for the Treatment of Cognitive Disorders in Down Syndrome	22-12-16	CI
Aelis Farma Announces Positive Results from Its Safety Trials in Healthy Volunteers and the Authorization to Start the First Trial in People with Down Syndrome with AEF0217	22-11-15	CI
Aelis Farma SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-26	CI
Indivior's Cannabis Use Disorder Treatment Enrolls First Patient For Phase 2b Trial	22-06-01	MT
Aelis Farma S.A. Announces the Inclusion of the 1st Patient in A Phase 2B Study of AEF0117 for the Treatment of Cannabis Use Disorder	22-06-01	CI
Biopharmaceutical Company Aelis Farma Secures $28 Million in Paris IPO	22-02-15	MT